ASH News Daily - Monday, December 12, 2011 - (Page A-16)

Page A–16 ® ASH NEWS DAILY Congratulations to winners of the National Marrow Donor Program® Awards for Best ASH Abstracts In celebration of the National Marrow Donor Program’s (NMDP) 25th anniversary and facilitation of 50,000 unrelated donor hematopoietic cell transplants, NMDP has partnered with ASH to provide awards, totaling $25,000, to the highest-scoring abstracts in 10 categories at the 2011 ASH Annual Meeting. View a short video about progress in transplant. Scan this code or view online at: marrow.org/ASH Scan this code BMT If Transplant is Dying, It Sure Is Enjoying Its Final Days By Michael r. BiShop, Md “ T to access video Award winners: Acute Lymphoblastic Leukemia—Biology & Pathophysiology Mark Y. Chiang, MD, PhD, University of Michigan Abstract #75 Acute Myeloid Leukemia—Biology & Pathophysiology Tanja A. Gruber, MD, PhD, St. Jude Children’s Research Hospital Abstract #757 Bone Marrow Failure Pekka Jaako, Lund University Abstract #727 Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution David Jacobsohn, MD, Children’s National Medical Center Abstract #151 Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities Riccardo Saccardi, MD, Eurocord Registry Abstract #650 Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence Saro Armenian, DO, MPH, City of Hope Abstract #330 Clinical Allogeneic and Autologous Transplantation: Results Claudio Anasetti, MD, H. Lee Moffitt Cancer Center & Research Institute Abstract #1 Health Services and Outcomes Research Can-Lan Sun, PhD, City of Hope Abstract #841 Myelodysplastic Syndromes Luca Malcovati, Fondazione IRCCS Policlinico San Matteo & University of Pavia Abstract #3 Non-Hodgkin Lymphoma—Biology, excluding Therapy Jens Lohr, MD, PhD, Dana-Farber Cancer Institute Abstract #259 Our achievements change lives. Our people inspire cures. Visit the NMDP booth (#1621) to join in the celebration. At Millennium: The Takeda Oncology Company located in Cambridge, MA, “We Aspire to Cure Cancer”. As a leading biopharmaceutical company focused on oncology, Millennium combines the agility, ideals and camaraderie of a start-up with the resources of Japan’s largest pharmaceutical company. The result is an entrepreneurial culture where the priorities are quality science and making a difference in patients’ lives and the communities we serve. Our people share a commitment to innovation in an environment where individual contributions are not just valued, but rewarded. Here you’ll enjoy outstanding benefits, a friendly, respectful atmosphere and a culture that promotes flexibility between your personal and professional life. Join Millennium and improve the lives of others while living yours to the fullest. To view our current career opportunities and apply online, visit: joinmillennium.com/37. ©2011 Millennium Pharmaceuticals, Inc. All rights reserved. 5 he report of my death was an exaggeration” – Mark Twain, 1897. This was Mr. Twain’s exact re- sponse to a report in the New York Journal, which ran a story of his death, although it was actually Twain’s cousin. This would not be the last time that Twain would be prematurely declared dead, as the New York Times ran a story of him being lost at sea in 1907 (his boat was actually delayed by fog). This is how some feel about hematopoietic stem cell transplantation (HSCT), as it has been said that transplant is “dead.” If it’s dead, or even dying, it sure is enjoying a prolonged death, as evidenced by the breath of the advances that will be shared today in 14, count them, 14 different Oral sessions that are directly related to HSCT. For those of you who are interested in transplantation, you will not be disappointed in the choices, which run from 7:00 in the morning all the way through to a final session that starts at 6:15 tonight. You are going to have to plan your day carefully, as there are a number of presentations with great scientific and clinical relevance. Dr. Annamaria Brioli, represent- ing the GIMEMA Italian Myeloma Network, will present results of an analysis of the effects of induction therapy with bortezomib, thalidomide, and dexamethasone upon the collection and engraftment potential of peripheral blood stem cells in myeloma patents in the first session of Cell Collection and Processing in the Elizabeth Ballroom DE, Manchester Grand Hyatt San Diego at 7:00 a.m. At 8:00 a.m., during the first experimental transplantation session, which will be held in Douglas Pavilion A at the Manchester Grand Hyatt San Diego, Dr. Cristiana Carniti will share her group’s results on the use of circulating micro RNAs as a tool for the early diagnosis of acute GVHD. To further muddy the water on the use of peripheral blood or bone marrow in allogeneic HSCT, Dr. Marco Mielcarek, representing his colleagues from Seattle, Stanford, and the City of Hope, will present long-term, follow-up results on their randomized trial of blood versus marrow, which was initially published in the New England Journal of Medicine in 2001. These results will be shared at 7:00 a.m. during the Clinical Allogeneic Transplantation Oral session in Douglas Pavilion D, Manchester Grand Hyatt San Diego. Next are the mid-morning ses- sions that will include updated results on the use of defibrotide in the treatment of hepatic veno-occlusive disease, presented by Dr. Paul Richardson at 10:30 a.m. during the Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities session in Douglas Pavilion B, Manchester Grand Hyatt San Diego. There will be several presentations on the use of transplantation in AML during the Clinical Allogeneic and Autologous Transplantation session in Douglas Pavilion D, Manchester Grand Hyatt San Diego. Following lunch and the Ernest Beutler Lecture, the sessions pick up again. One of the highlights of the afternoon will be the presentation of the results of the randomized phase III Trial of BEAM plus 131 iodine-Tositumomab versus BEAM plus rituximab »» TRANSPLANT Page A-19 Image: colored scanning electron micrograph (SEM) of a lung cancer cell. Monday, December 12, 2011 NMDP_Ad_ASH_News Daily_V4.indd 1 #####; NOV 2011 9/30/11 2:47 PM

Table of Contents for the Digital Edition of ASH News Daily - Monday, December 12, 2011

ASH News Daily - Monday, December 12, 2011

https://www.nxtbookmedia.com